Search Results - "Marcondes, Mario Q."

Acute-phase protein α1-antitrypsin--a novel regulator of angiopoietin-like protein 4 transcription and secretion by Frenzel, Eileen, Wrenger, Sabine, Immenschuh, Stephan, Koczulla, Rembert, Mahadeva, Ravi, Deeg, H Joachim, Dinarello, Charles A, Welte, Tobias, Marcondes, A Mario Q, Janciauskiene, Sabina

“…The angiopoietin-like protein 4 (angptl4, also known as peroxisome proliferator-activated receptor [PPAR]γ-induced angiopoietin-related protein) is a…”
Get full text

Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies by Shah, Nina, Perales, Miguel-Angel, Turtle, Cameron J, Cairo, Mitchell S, Cowan, Andrew J, Saeed, Hayder, Budde, Lihua E, Tan, Alan, Lee, Zachary, Kai, Kazuharu, Marcondes, Mario Q, Zalevsky, Jonathan, Tagliaferri, Mary A, Patel, Krina K

“…NKTR-255 is an investigational polyethylene glycol-modified recombinant human IL-15 (rhIL-15) receptor agonist, designed to improve the immunotherapeutic and…”
Get full text

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy by Hirayama, Alexandre V., Chou, Cassie K., Miyazaki, Takahiro, Steinmetz, Rachel N., Di, Henna A., Fraessle, Simon P., Gauthier, Jordan, Fiorenza, Salvatore, Hawkins, Reed M., Overwijk, Willem W., Riddell, Stanley R., Marcondes, Mario Q., Turtle, Cameron J.

“…•Polymer-conjugated IL-15 (NKTR-255) induced CD8+ and CD4+ T-cell and natural killer cell proliferation in nonhuman primates.•NKTR-255 enhanced the efficacy of…”
Get full text

α1-Antitrypsin Combines with Plasma Fatty Acids and Induces Angiopoietin-like Protein 4 Expression by Frenzel, Eileen, Wrenger, Sabine, Brügger, Britta, Salipalli, Sandeep, Immenschuh, Stephan, Aggarwal, Nupur, Lichtinghagen, Ralf, Mahadeva, Ravi, Marcondes, A Mario Q, Dinarello, Charles A, Welte, Tobias, Janciauskiene, Sabina

“…α1-Antitrypsin (A1AT) purified from human plasma upregulates expression and release of angiopoietin-like protein 4 (Angptl4) in adherent human blood monocytes…”
Get full text

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) by Vinaud Hirayama, Alexandre, Chou, Cassie, Maloney, David G., Marcondes, Mario Q., Turtle, Cameron J.

Get full text

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma by Perales, Miguel-Angel, Ahmed, Sairah, Dahiya, Saurabh, Riedell, Peter A., McGuirk, Joseph P., Oluwole, Olalekan O., Chaudhry, Sohail A., Lee, Zachary, Dai, Stanley, Dixit, Neha, Fanton, Christie, Marcondes, Mario Q., Zalevsky, Jonathan, Tagliaferri, Mary A., Turtle, Cameron J.

Get full text

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL) by Chu, Yaya, Jiang, Susiyan, Jiang, Jian, Tian, Meijuan, Lee, Dean Anthony, Madakamutil, Loui, Marcondes, Mario Q., Klein, Christian, Cairo, Mitchell S

“…Background: The CD20 molecule is universally expressed by normal B cells in all stages of development, from the pre-B cell up to the mature plasma cell as well…”
Get full text

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies by Patel, Krina, Shah, Nina, Tan, Alan, Cowan, Andrew J, Turtle, Cameron J., Hofmeister, Craig C, Choi, Taewoong, Saeed, Hayder, Chavez, Julio C., Pianko, Matthew J., Gandhi, Mitul, Chaudhry, Sohail A., Lee, Zachary, Dixit, Neha, Fanton, Christie, Wang, Xiaoli, Xu, Heng, Marcondes, Mario Q., Tagliaferri, Mary A., Zalevsky, Jonathan, Perales, Miguel-Angel

Get full text

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model by Miyazaki, Takahiro, Kivimäe, Saul, Hennessy, Marlene, Pena, Rhoneil, Quach, Phi, Moffet, Andrew, Nieves, Wildaliz, Zhang, Ping, Marcondes, Mario Q., Madakamutil, Loui, Zalevsky, Jonathan

“…Background IL-15 is a cytokine that activates and provides survival benefit to T and NK cells and has great potential as an immunotherapeutic agent for the…”
Get full text

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model by Chou, Cassie, Fraessle, Simon, Steinmetz, Rachel, Hawkins, Reed M., Phi, Tinh-Doan, Busch, Dirk, Miyazaki, Takahiro, Marcondes, Mario Q., Riddell, Stanley R., Turtle, Cameron J.

“…Background CD19 CAR T immunotherapy has been successful in achieving durable remissions in some patients with relapsed/refractory B cell lymphomas, but disease…”
Get full text

Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study by Turtle, Cameron J., Budde, Elizabeth, Patel, Krina K., Perales, Miguel-Angel, Cowan, Andrew J., Saeed, Hayder, Chavez, Julio C., Hirayama, Alexandre V., Kirchmeier, Delaney R., Janakiram, Murali, Wu, Kai, Fong, Lawrence, Lee, Zachary, Dixit, Neha, Wang, Xiaoli, Kai, Kazuharu, Marcondes, Mario Q., Zalevsky, Jonathan, Shah, Nina

“…Background: Autologous T cells engineered to express a CD19 or BCMA-specific chimeric antigen receptor (CAR) have shown high overall response rates in…”
Get full text

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies by Shah, Nina, Tan, Alan, Budde, Elizabeth, Hofmeister, Craig C., Cowan, Andrew J., Perales, Miguel-Angel, Choi, Taewoong, Saeed, Hayder, Chavez, Julio C., Ye, Jing C., Cairo, Mitchell S., Rizzieri, David A., Orloff, Gregory J., Lee, Zachary, Dixit, Neha, Nieves, Wildaliz, Zhao, Qiang, Wang, Xiaoli, Kai, Kazuharu, Marcondes, Mario Q., Tagliaferri, Mary A., Zalevsky, Jonathan, Patel, Krina K.

“…▪ Introduction: NKTR-255, an investigational novel polymer-conjugated recombinant human interleukin (IL)-15 agonist, maintains the full spectrum of IL-15…”
Get full text

Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey by Miyazaki, Takahiro, Kuo, Peiwen, Maiti, Mekhala, Obalapur, Palakshi, Addepalli, Murali, Rubas, Werner, Sims, Paul, Zhang, Ping, Marcondes, Mario Q., Madakamutil, Loui, Zalevsky, Jonathan

“…Introduction IL-15 is a common gamma chain cytokine that activates and provides a survival benefit to T-cells and NK cells and has long been recognized as…”
Get full text

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma by Shah, Nina D., Turtle, Cameron J., Cowan, Andrew J., Chavez, Julio C., Budde, Lihua E, Marcondes, Mario Q., Lee, Zachary, Lin, Wei, Zalevsky, Jonathan, Tagliaferri, Mary, Patel, Krina K.

“…Background: IL-15-mediated responses have been shown to have a crucial role in the development, function, and survival of CD8+ T cells, natural killer (NK)…”
Get full text

201 - Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL) by Chu, Yaya, Tian, Meijuan, Marcondes, Mario Q., Overwijk, Willem W, Lee, Dean Anthony, Klein, Christian, Cairo, Mitch S.

Get full text

Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL) by Chu, Yaya, Tian, Meijuan, Marcondes, Mario Q., Overwijk, Willem W, Lee, Dean Anthony, Klein, Christian, Cairo, Mitch S.

Get full text

Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-Mcam Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells by Luo, Wen, Gardenswartz, Aliza, Chu, Yaya, Rosenblum, Jeremy, Ayello, Janet, Marcondes, Mario Q., Overwijk, Willem W, Cripe, Timothy P, Cassady, Kevin A, Lee, Dean Anthony, Cairo, Mitch S.

Get full text

27 - Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-Mcam Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells by Luo, Wen, Gardenswartz, Aliza, Chu, Yaya, Rosenblum, Jeremy, Ayello, Janet, Marcondes, Mario Q., Overwijk, Willem W, Cripe, Timothy P, Cassady, Kevin A, Lee, Dean Anthony, Cairo, Mitch S.

Get full text

Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL by Jackson, Clayton, Shiraz, Parveen, Iglesias, Maria, Egeler, Emily, Sahaf, Bita, Arai, Sally, Bharadwaj, Sushma, Johnston, Laura, Lowsky, Robert, Meyer, Everett H., Negrin, Robert S., Rezvani, Andrew R., Weng, Wen-Kai, Shizuru, Judith A., Marcondes, Mario Q., Tagliaferri, Mary A., Sidana, Surbhi, Frank, Matthew J., Smith, Melody, Feldman, Steven, Miklos, David B., Mackall, Crystal, Syal, Shriya, Patil, Sunita, Reynolds, Warren D., Muffly, Lori

Get full text

274 - Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL by Jackson, Clayton, Shiraz, Parveen, Iglesias, Maria, Egeler, Emily, Sahaf, Bita, Arai, Sally, Bharadwaj, Sushma, Johnston, Laura, Lowsky, Robert, Meyer, Everett H., Negrin, Robert S., Rezvani, Andrew R., Weng, Wen-Kai, Shizuru, Judith A., Marcondes, Mario Q., Tagliaferri, Mary A., Sidana, Surbhi, Frank, Matthew J., Smith, Melody, Feldman, Steven, Miklos, David B., Mackall, Crystal, Syal, Shriya, Patil, Sunita, Reynolds, Warren D., Muffly, Lori

Get full text